In Oct 2007, the FDA announced that the labeling for all PDE5 inhibitors, including tadalafil, needs a far more popular warning in the possible hazard of unexpected hearing loss as the result of post-marketing and advertising studies of momentary deafness associated with use of PDE5 inhibitors.[19]